Swati Pradhan sees about 12 obesity patients a day at her small clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk A/S’s blockbuster weight-loss drug at half the price.
